Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Boyd

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|January 10, 2018
Combination ART: are two drugs as good as three?Mark A Boyd, David A Cooper
AIDS (London, England)|September 25, 2007
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical researchMark A Boyd, David A Cooper
The Lancet. HIV|April 3, 2016
Tenofovir alafenamide: safer, but questions remainMark A Boyd, David A Cooper
The Lancet. Infectious Diseases|October 1, 2013
SPRING-2 the future of antiretroviral therapyMark A Boyd, David A Cooper
The Lancet. HIV|January 15, 2016
Novel antiretroviral agents and universal access to HIV careMark A Boyd, David A Cooper
AIDS Research and Therapy|December 14, 2018
Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?Michelle L Giles, Coral Gartner, Mark A Boyd
The Lancet. HIV|October 11, 2017
Towards a universal second-line fixed-dose combination ARTMark A Boyd, David A Cooper, Charles F Gilks
The Lancet. HIV|July 30, 2016
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysisAmit C Achhra, Gwamaka Mwasakifwa, Janaki Amin, et al.
AIDS (London, England)|July 5, 2021
Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failureGwamaka Eliudi Mwasakifwa, Janaki Amin, Anthony Kelleher, et al.
AIDS (London, England)|April 11, 2006
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosisMark A Boyd, David M Burger, Praphan Phanuphak, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|January 10, 2018
Combination ART: are two drugs as good as three?Mark A Boyd, David A Cooper
AIDS (London, England)|September 25, 2007
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical researchMark A Boyd, David A Cooper
The Lancet. HIV|April 3, 2016
Tenofovir alafenamide: safer, but questions remainMark A Boyd, David A Cooper
The Lancet. Infectious Diseases|October 1, 2013
SPRING-2 the future of antiretroviral therapyMark A Boyd, David A Cooper
The Lancet. HIV|January 15, 2016
Novel antiretroviral agents and universal access to HIV careMark A Boyd, David A Cooper
AIDS Research and Therapy|December 14, 2018
Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?Michelle L Giles, Coral Gartner, Mark A Boyd
The Lancet. HIV|October 11, 2017
Towards a universal second-line fixed-dose combination ARTMark A Boyd, David A Cooper, Charles F Gilks
The Lancet. HIV|July 30, 2016
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysisAmit C Achhra, Gwamaka Mwasakifwa, Janaki Amin, et al.
AIDS (London, England)|July 5, 2021
Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failureGwamaka Eliudi Mwasakifwa, Janaki Amin, Anthony Kelleher, et al.
AIDS (London, England)|April 11, 2006
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosisMark A Boyd, David M Burger, Praphan Phanuphak, et al.
Pageof 10